Skip to main content
. 2022 Nov 9;61:129–138. doi: 10.1016/j.mattod.2022.11.001

Figure 3.

Figure 3

Multianalyte detection capability of BiosensorX. (a) 3D rendering of the stacked BiosensorX. (b-f) Personalized ß-lactam antibiotic dosing in a simulated COVID-19 patient. (b) Methodology of simultaneous measurement of antibiotic concentration and detection of viral RNA in clinical samples. (c) Overview of the drug clearance behavior in a simulated COVID-19 patient (d) before, (e) 5 minutes, (f) 240 minutes after “antibiotic administration” (N = 1). (g-i) Clinical samples from a healthy subject and two COVID-19 patients analyzed with BiosensorX. Current densities for (g) a healthy subject, (h) a patient with Ct 17.8 and (i) a patient with Ct 19. Signals obtained from the samples of diseased patients were normalized to their respective target-equivalents obtained from the healthy subject and are therefore presented in arbitrary units. N = 2, Error bars represent + SD.